Kaskela Law LLC announces that it is investigating Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) (“Zentalis”) on behalf of the company’s investors.
Since September 2023, shares of Zentalis’s common stock have declined in value from a trading price of over $25.00 per share to a current trading price of less than $1.00 per share, a cumulative decline of 60% in value.
The investigation seeks to determine whether the company’s officers and/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions.
Zentalis stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by completing the form on this page, for additional information about this investigation and their legal rights and options.